Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT-4: KarXT for Alzheimer’s disease-related psychosis
CTR20260255Phase 3Active
- Sponsor
- Karuna Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline in Alzheimer's disease (AD), sponsored by Karuna Therapeutics. Started Apr 2026; status: active.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20260255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260255.